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Summary
We demonstrate a novel tumor-promoting role of myeloid immune suppressor GrCD11b cells, which are evident in
cancer patients and tumor-bearing animals. These cells constitute approximately 5% of total cells in tumors. Tumors
coinjected with GrCD11b cells exhibited increased vascular density, vascular maturation, and decreased necrosis.
These immune cells produce high levels of MMP9. Deletion of MMP9 in these cells completely abolishes their tumor-
promoting ability. GrCD11b cells were also found to directly incorporate into tumor endothelium. Consistent with this
observation, GrCD11b cells acquire endothelial cell (EC) properties in tumor microenvironment and proangiogenic
culture conditions. Our data provide evidence that GrCD11b cells of immune origin induced by tumors directly contribute
to tumor growth and vascularization by producing MMP9 and differentiating into ECs.
Introduction cells (EPCs), but rather on a hematopoietic cell population (i.e.,
CD45- and CD11b-positive, but CD31-negative) that homed
Tumors must escape from host immune surveillance in order specifically to the tumors and contributed indirectly to neovas-
to survive and grow. The development, progression, and metas- cularization. Recently, a report showed the absence of BM-
tasis of tumors also depend on tumor blood vessels. A number derived EC precursors in the enhanced tumor growth in 3-
of recent findings demonstrate that angioblasts, the progenitors integrin null mice, which they instead related to circulating blood
for endothelial cells contributing to embryonic vascular develop- cells such as macrophages (Taverna et al., 2004). All of these
ment, also contribute to tumor vascular formation (Asahara et studies show the intense research and debate on this subject.
al., 1997; Lyden et al., 2001; Rafii et al., 2002). These progenitor Clearly, how host hematopoietic cells contribute to tumor
cells were further identified as VEGFR2-positive bone marrow growth, especially tumor angiogenesis, needs to be further elu-
(BM)-derived cells. Transplantation of wild-type BM to Id mutant cidated.
mice (Lyden et al., 1999) or placental growth factor null mice The host contribution to tumor progression is reflected by
(Carmeliet et al., 2001; Hattori et al., 2002) restored their ability the roles of tumor infiltrating cells, which orchestrate the tumor
to form tumor blood vessels and rescued tumor growth in these microenvironment, and participate in the neoplastic process by
mutant mice. These results demonstrate that vasculogenesis is fostering proliferation, survival, and metastasis (Coussens and
sufficient to restore tumor vascular formation ability in these Werb, 2002). These infiltrating cells promote tumor angiogenesis
genetic models. However, contradicting data (De Palma et al., by producing angiogenic factors and matrix-degrading enzymes
such as matrix metalloproteinase 9 (MMP9), a critical regulator2003) showed the absence of transplanted BM cells in tumor
endothelium. Of interest, the authors discovered that BM contri- of tumor angiogenesis, vasculogenesis, and metastasis (Frid-
man et al., 2003; Hamano et al., 2003; Hiratsuka et al., 2002).bution to tumor vessels relied not on the endothelial progenitor
S I G N I F I C A N C E
Escape from immune surveillance and promotion of tumor angiogenesis are essential for tumors to grow and progress. These two
aspects are governed by the immune system and the angiogenic network of the host. In this report, an expansion of myeloid immune
suppressor GrCD11b cells was found to directly promote tumor growth through the mechanisms of tumor angiogenesis and
vasculogenesis. The proangiogenic role of myeloid immune suppressor cells induced by tumors might constitute a critical mechanism
by which tumors subvert their host. Interventions aimed at eliminating these cells may improve antitumor immune response and
concurrently inhibit tumor angiogenesis.
CANCER CELL : OCTOBER 2004 · VOL. 6 · COPYRIGHT  2004 CELL PRESS 409
A R T I C L E
Studies have shown that MMP9 functions as an angiogenic 30–35 days after tumor inoculation, but only 3% in the spleens
of normal mice (Figures 1C and 1D). In the 3LL (which grewswitch during tumorigenesis by releasing vascular endothelial
growth factor (VEGF) from the matrix (Bergers et al., 2000). In significantly quicker) model, GrCD11b cells were also sig-
nificantly increased to over 12% in spleens of tumor-bearingaddition, there has been an increasing recognition of strong
adaptive responses of cells in response to environmental stimuli mice 21–28 days after tumor inoculation compared to 0.9%
in normal spleens (Supplemental Figure S1 at http://www.(Fernandez Pujol et al., 2001; Harraz et al., 2001; Schmeisser
et al., 2001). ECs and hematopoietic cells share the same pro- cancercell.org/cgi/content/full/6/4/409/DC1/). In addition, we
observed that the production of GrCD11b cells and thegenitors, hemangioblasts. The monocyte/macrophage/dendritic
cell (DC) system is closely related to ECs, and it has been tumor infiltration of these cells increased as tumor size increased
and with the duration of tumor growth (Figures 1E–1G). Thesespeculated that these cells might differentiate into ECs under
certain conditions. Understanding the role of hematopoietic data suggest that tumors affect hematopoiesis of the tumor
hosts, manifested by the increase of GrCD11b cells in bothcells in the tumor microenvironment is of immense interest.
Accumulating evidence since the 1980s has demonstrated spleens and tumors.
To further characterize the composition of GrCD11bthat myeloid immune suppressor GrCD11b cells, of myeloid
macrophage/DC lineage, are significantly increased in spleens cells, these cells were sorted from spleens of normal and tumor-
bearing mice using FACS, then spun onto glass slides, stainedand BM of animals bearing large tumors and in conditions asso-
ciated with impaired immune reactivity (Bronte et al., 2000; by H&E, and examined by a hematology pathologist in a blinded
fashion. Each subset of cells was counted, and the percentageGabrilovich et al., 1999; Kusmartsev and Gabrilovich, 2002;
Melani et al., 2003; Serafini et al., 2004). These cells are also was determined (Figures 1H–1J). We found that there was a
significant increase in the whole spectrum of myeloid lineagefound in the peripheral blood of cancer patients, including lung,
breast, and head and neck cancer (Almand et al., 2001; Young cells, including myeloblasts, promyelocytes, myelocytes, meta-
myelocytes, bands, and neutrophils, ranging from less differenti-and Lathers, 1999). GrCD11b cells express CD11b, a spe-
cific marker for myeloid cells of the macrophage lineage, and ated to terminally differentiated myeloid cells, in the tumor-
bearing mice compared to that of normal controls (p  0.05)a marker for granulocytes, Gr-1. GrCD11b cells are known
to be immune suppressive (Almand et al., 2001; Serafini et al., (Figure 1J). These data reveal that tumors are associated with
an increased fraction of myeloid cells.2004; Young and Lathers, 1999). They express abnormally low
levels of MHC class II molecules and low/undetectable levels
of costimulatory molecules. They are unable to process and Tumor growth was increased when tumor cells were
coinjected with GrCD11b cellspresent antigens, and therefore do not induce effective antitu-
mor responses (Bronte et al., 2000; Gabrilovich et al., 1996; It is well described that GrCD11b cells are associated with
immune suppression in tumor-bearing hosts, but it is unclearKusmartsev and Gabrilovich, 2002). Despite the data defining
the immune-suppressive effect of these cells, it is unclear whether these cells affect tumor growth directly. To examine
this, we sorted GrCD11b cells from the spleens of micewhether GrCD11b cells play other roles in tumor growth.
Here we show these myeloid immune suppressor cells actively bearing large MC26 tumors using FACS (Figure 2A). We
achieved approximately 91% purity of GrCD11b cells, withcontribute to tumor angiogenesis by producing MMP9, and can
differentiate into ECs. Our data demonstrate a novel mechanism the rest composed mostly of dead cells and debris. MC26 at
5 105 were coinjected subcutaneously (s.c). with GrCD11bused by tumors to exploit the host and thus promote tumor
development and growth. cells (0.5  105), sorted from tumor-bearing mice or normal
mice, into BALB/c mice. Tumor size was measured by cali-
pers. We found that tumor volume and growth rate are signifi-Results
cantly higher when coinjected with tumor-derived GrCD11b
cells than tumor cells alone or tumor cells coinjected withGrCD11b cells infiltrated into tumors and were
dramatically increased in tumor-bearing hosts GrCD11b cells from normal mice (p  0.05) (Figure 2B).
However, this difference diminished approximately 28 days afterThe possibility that GrCD11b cells may contribute to tumor
angiogenesis led us to examine whether these cells infiltrate tumor inoculation for the MC26 model (Figure 2B) and 21 days
for the 3LL model (Figure 5A). This is likely due to the significantinto tumors. Single cell suspensions from tumor tissues were
labeled with fluorescence-conjugated antibodies, and analyzed production of GrCD11b cells of the hosts bearing large tu-
mors later in the experiments (Figures 1E–1G), which predomi-by flow cytometry. GrCD11b cells comprised on average
5.64% of total tumor cells (Figures 1A and 1B) in a colorectal nate the GrCD11b cells we coinjected. These data support
the hypothesis that GrCD11b cells directly promote tumorcancer (MC26) model, and 5.41% in a Lewis lung carcinoma
(3LL) model (Supplemental Figure S1 at http://www.cancercell. growth.
org/cgi/content/full/6/4/409/DC1/). It was previously reported
that the number of GrCD11b cells was greatly increased in Increased tumor angiogenesis, vascular maturation,
and decreased tumor cell apoptosis and tumorthe spleens of mice with large tumors. This was assessed in
our two experimental models: Balb/c mice were inoculated s.c. necrosis were observed in tumors coinjected
with GrCD11b cellswith 5  105 MC26 cells, and C57BL/6 mice with 5  105 3LL
cells. Single cell suspensions from spleens of normal mice and The MC26 tumors were harvested 21 days after tumor inocula-
tion. We observed more visible blood vessels on the surface ofmice with tumors equal or larger than 1.5 cm in diameter were
made, and the presence of GrCD11b cells was evaluated the tumors that received a coinjection of MC26 and tumor-
derived GrCD11b cells (Figure 3B) than MC26 cells aloneby flow cytometry. GrCD11b cells made up over 40% of
the cell population in spleens of MC26-tumor-bearing mice (Figure 3A). It is known that tumor necrosis results when tumor
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Figure 1. GrCD11b cells infiltrated into tumor tissues and were significantly increased in spleens of tumor-bearing mice
A and B: Flow cytometry analysis to assess the infiltrating GrCD11b cells in MC26 tumors 35 days after tumor inoculation (A), as quantified in B. ** indicates
p  0.01.
C and D: GrCD11b cells in spleens of normal and MC26 tumor-bearing mice 35 days after tumor inoculation by flow cytometry analysis (C), as quantified
in D. ** indicates p  0.01.
E–G: 5  105 MC26 cells were injected s.c. in Balb/c mice. Tumor growth was shown (E). The percentage of GrCD11b cells in spleens (F) and tumor
tissues (G) of tumor-bearing mice was analyzed by flow cytometry. n  5 mice per group.
H–J: Sorted GrCD11b cells from the spleens of normal mice (H) and MC26 tumor-bearing mice (I) were stained with H&E. Cell compositions of the
GrCD11b populations were quantified (J) (4 or more mice per group). *, p  0.05.
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GrCD11b cells derived from tumor mice than those derived
from normal mice (p  0.05) (Figure 4E), with an average of
25.92  2.4 and 17.56  2.2 (p  0.05) for the MC26 tumor
model. Similar results were observed in the 3LL tumor model,
with an average of 120  15.4 and 77  8.1 vessels (p  0.05)
for the 3LL coinjected with GrCD11b cells of tumor mice
and normal mice, respectively (Supplemental Figure S2 at http://
www.cancercell.org/cgi/content/full/6/4/409/DC1/). Consider-
ing the difference in tumor volume between the two groups, the
difference of total blood vessels is actually more pronounced.
Very interestingly, we found many viable islands consisting of
tumor cells, CD31-positive cells, and blood vessels within large
necrotic regions in tumors derived from a coinjection of tumor
cells with tumor derived GrCD11b cells (Figure 4D and Sup-
plemental Figure S2D). CD31-positive cells were abundant and
grouped around tumor blood vessels. Some of these cells were
seen within the tumor endothelium (Figure 4D), which was
greatly reduced in tumors derived from coinjected with normal
GrCD11b cells (Figure 4C, Supplemental Figure S2). In addi-
tion, tumor sections were costained with antibodies against
CD31 and SMC ( smooth muscle actin). The percentage of
SMC and CD31 double-positive vessels from the total of
CD31 vessels was used as an index for vessel maturation/
stability. We found significantly more SMC-positive vessels in
MC26 tumors coinjected with tumor-derived GrCD11b cells
than controls (Figures 4F–4H) (p 0.05); this increase correlated
with a significant reduction in apoptotic cells in tumors with
coinjection (Figures 4I–4K) (p  0.05). The data is in agreement
with a recent publication that stromal MMP9 regulates the vas-
cular architecture by promoting pericyte recruitment (Chantrain
et al., 2004). Collectively, our data indicate that coinjection of
Figure 2. Tumor growth of MC26 was significantly increased when coin- tumor cells with tumor-derived GrCD11b cells is associated
jected with tumor derived GrCD11b cells
with increased tumor angiogenesis, vascular maturation, and
A: Single-cell sorting of GrCD11b cells from spleens of MC26 tumor- decreased tumor apoptosis and necrosis.
bearing mice 35 days after tumor inoculation using CD11b-FITC and Gr-1-
PE antibodies. Flow cytometry analysis of GrCD11b cells before and
GrCD11b cells contributed to tumor angiogenesisafter sorting was shown.
B: Isograft models of tumor growth with GrCD11b cells. 5  105 MC26 through the production of MMP9
cells and sorted 0.5  105 GrCD11b cells from tumor mice were injected We observed increased tumor angiogenesis, reduced tumor
s.c. in Balb/c mice. MC26 cells alone and GrCD11b cells from normal
necrosis, and enhanced tumor growth from the coinjection ofmice were used as controls. Results were presented as the mean  SEM
MC26 cells with tumor-derived GrCD11b cells. We next in-(5–8 mice per group). *, p  0.05 and §, p  0.05.
vestigated the mechanisms involved in this process. Previous
studies demonstrate that tumor-infiltrating neutrophils, macro-
phages, and mast cells produce MMP9 and contribute to skin
carcinogenesis (Coussens et al., 2000). MMP9 is also knowngrowth outstrips its blood supply. Therefore, we examined tu-
to promote tumor angiogenesis by regulating the bioavailabilitymor necrosis using GdDTPA contrast agent-enhanced magnetic
of VEGF (Bergers et al., 2000; Rodriguez-Manzaneque et al.,resonance imaging (MRI). We found that tumors were signifi-
2001). To test the role of MMP9 in GrCD11b cells, we sortedcantly less necrotic when coinjected with GrCD11b cells
GrCD11b cells from spleens of MMP9 null and wt tumor-(Figure 3D), compared to tumor cells alone (p  0.05) (Figure
bearing mice, respectively. These cells were then coinjected3C). The mean fractional necrosis was 15% for MC26 coinjected
with syngeneic 3LL tumor cells into wt C57Bl/6 mice, the geneticwith GrCD11b cells, with 31% for MC26 cells alone (Figure
background of the MMP9 null mice used in this study. Tumor3E). Histological analysis for hypoxia in tumor sections showed
size was then measured. Tumors from 3LL cells coinjected withlarge numbers of hypoxic cells in the center of the tumors with-
MMP9 null GrCD11b cells grew significantly slower thanout coinjection (Figure 3F), but many fewer hypoxic cells in the
those derived from coinjection with GrCD11b cells from atumors coinjected with GrCD11b cells (Figure 3G).
wt background (p  0.001) (Figure 5A). In fact, it appearedTo further investigate whether increased tumor vascularity
that MMP9 null GrCD11b cells suppressed tumor growthcould explain the increased tumor growth rate, we stained tumor
samples with an anti-CD31 antibody (Figures 4A–4D). Blood compared to the control 3LL alone (p  0.021). This difference
diminished at later time points, likely due to the large productionvessels were counted in more than 10 randomly selected high
power fields from 4 independent MC26 tumors (Figure 4E) in a of GrCD11b cells from the hosts. These tumors also have
decreased tumor blood vessel counts (p  0.05) (Figure 5B).blinded evaluation. A significantly higher blood vessel density
was observed in tumors derived from MC26 coinjected with To confirm the results, GrCD11b cells from normal and
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Figure 3. Increased tumor blood vessels and de-
creased tumor necrosis in MC26 tumors coin-
jected with GrCD11b cells when compared
to MC26 cells alone
A and B: More blood vessels on the surface of
tumors derived from MC26 cells coinjected with
tumor derived GrCD11b cells (B) than with
MC26 alone (A) 21 days after the tumor inocula-
tion. Scale bar: 0.25 mm.
C–E: MR imaging of tumors derived from MC26
alone (C) or MC26 cells coinjected with tumor
derived GrCD11b cells (D), as quantification
of live and dead tumor volume (E). p  0.05, n
3 pairs.
F and G: Immunohistochemistry of pimonidazole
adducts for hypoxia cells (brown color) in tumor
sections from MC26 alone (F) and MC26 coin-
jected with GrCD11b cells (G).
MC26 tumor-bearing mice were isolated, and cell lysates were no difference of VEGF levels between the two groups, and no
difference of VEGF production was found in the culture media ofanalyzed by gelatin zymography for MMP activity. It is very
clear that GrCD11b cells derived from tumor-bearing mice normal and tumor-derived GrCD11b cells (data not shown).
These results suggest that the difference of VEGFR2 activationproduced high levels of pro-MMP9 and MMP9 compared with
cells derived from normal mice. In contrast, there was no sig- is likely due to the bioavailability of VEGF. Therefore, we evalu-
ated VEGF release in tumor tissues. We found that there wasnificant difference in MMP2 levels between the two groups (Fig-
ure 5C). In addition, in situ hybridization of the tumor sections significantly more VEGF released in MC26 tumor coinjected
with GrCD11b from tumor-bearing mice than from normalshowed significantly more MMP9-positive cells in 3LL tumors
coinjected with tumor-derived GrCD11b cells than the tumor mice (Figure 6C) (p  0.01). Addition of GM6001, a MMP inhibi-
tor, significantly reduced VEGF release from the tumor tissuescell alone (Figures 5D and 5E). MMP9-positive cells were visible
compared to the untreated group (Figure 6C) (p  0.01). Afterthroughout the tumors as well as around and in the vascular
examination the angiogenic function of VEGF released from thewalls of tumors coinjected with GrCD11b cells (Figure 5E),
tumors, we found MC26 tumors coinjected with GrCD11bwhich is similar to the immunohistochemical staining of CD31 in
cells from tumor-bearing mice showed stronger effects in induc-tumor sections (Figure 4D). Collectively, these data demonstrate
ing EC migration than those coinjected with GrCD11b cellsthat production of MMP9 by GrCD11b cells contributes to
from nontumor mice (p 0.05). Addition of either a VEGF inhibi-tumor angiogenesis and tumor growth.
tor or MMP inhibitor blocked EC migration induced by the tumor
tissues (p  0.01) (Figure 6D). Collectively, these data suggestMMP9 derived from GrCD11b cells regulated VEGF
bioavailability in tumors and sKitL (soluble that GrCD11b cells produce MMP9 that regulates bioavail-
ability of VEGF and promotes tumor angiogenesis.Kit-ligand) release in BM
Our data demonstrated an essential role of MMP9 of MMP9 is also known to release sKitL in BM, permitting
the transfer of hematopoietic stem cells from the quiescent toGrCD11b cells in tumor promotion. We next studied the
molecular mechanisms. MMP9 has been shown to function as proliferative niche (Heissig et al., 2002). Therefore, we examined
the effects of host MMP9 on GrCD11b cell production andan angiogenic switch and release VEGF from extracellular matrix
(Bergers et al., 2000); therefore, we investigated the association tumor infiltration. Spleens, BM, and tumors were harvested from
both normal and 3LL-bearing wt and MMP9 null mice, and theof VEGFR2/VEGF using an antibody that only recognizes the
complex. We found that there were significantly more VEGFR2/ presence of GrCD11b cells was analyzed. We found that
deletion of MMP9 in hosts significantly inhibited the productionVEGF-positive vessels in the MC26 tumors coinjected with tu-
mor-derived GrCD11b cells than in controls (Figures 6A and of GrCD11b cells in spleens (Figure 6E, p  0.01) and BM
(Figure 6F, p  0.05). There was also a significant reduction6B). Immunohistochemical analysis of tumor sections showed
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Figure 4. Increased tumor blood vessel density
and vascular stability and decreased apoptosis
from MC26 tumors coinjected with tumor derived
GrCD11b cells
A–D: Tumor sections were stained with an anti-
CD31 antibody (brown color). Blood vessels in
live (A and B) and necrotic regions (C and D)
of tumors derived from MC26 coinjected with
GrCD11b cells derived from normal mice (A
and C) and tumor-bearing mice (B and D) 21
days after the tumor inoculation are shown.
E: Tumor blood vessels were counted in 10 ran-
domly selected fields from MC26 tumors 21 days
after the tumor inoculation. *, p  0.05.
F–H: Immunofluorescent analysis of SMC
(green) and CD31 (red) double-positive vessels,
as indicated by arrows in tumor sections from
MC26 coinjected with GrCD11b cells of nor-
mal mice (F) and tumor-bearing mice (G). DAPI
staining (blue) for nuclei. The percentage of
SMC and CD31 double-positive vessels from the
total of CD31-positive vessels was quantified (H).
* indicates p  0.05
I–K: TUNEL assay for apoptotic cells as indicated
by arrows in tumor sections of MC26 coinjected
with GrCD11b cells of normal (I) and tumor-
bearing mice (J). Quantification of apoptotic
cells in these tumor sections (K). *, p  0.01.
of GrCD11b infiltrating in tumors from MMP9 null mice spleens of MC26 tumor-bearing mice and labeled them with a
than from wt mice (Figure 6G, p  0.01). Finally, we investi- vital dye 5-CFDA, and coinjected with MC26 cells into Balb/c
gated sKitL release from BM stromal cells cocultured with mice. Frozen tumor sections collected 21 days after tumor injec-
GrCD11b cells. Both BM stromal cells and GrCD11b tion were examined under a fluorescence microscope. Strik-
cells expressed sKitL. Addition of GrCD11b cells from MC26 ingly, we found GrCD11b cells lining the endothelial wall of
tumor-bearing mice significantly increased the release of sKitL tumor blood vessels (Figure 7A). Some of them showed the
from BM stromal cells, compared to GrCD11b cells derived long thin shape of ECs (Figures 7A and 7B). Some labeled
from normal mice (p 0.01). This could be blocked with a MMP GrCD11b cells still retained a rounded shape, and clustered
inhibitor GM6001 (Figure 6H, p 0.01). Together, our data show around tumor blood vessels in a manner similar to what we
that host MMP9 regulates GrCD11b cells production and have observed in CD31 staining (Figure 4D). Immunostaining of
tumor infiltration. MMP9 from GrCD11b cells regulates the
tumor sections with an anti-CD31 antibody confirmed that therelease of sKitL in BM and potentially affects production and
fluorescently labeled cells were indeed tumor endothelium (Fig-mobilization of endothelial and hematopoietic stem cells in BM.
ure 7B). To further verify this observation, we used Rosa-26
mice, a transgenic line that ubiquitously expresses -galactoci-GrCD11b cells directly incorporated
dase. Sorted GrCD11b cells from 3LL tumor-bearing Rosa-into tumor endothelium
26 mice were coinjected with 3LL cells into C57BL/6 mice.To further investigate the contribution of GrCD11b cells to
tumor growth in vivo, we sorted GrCD11b cells from the Tumor samples were analyzed for -gal expression. We ob-
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fore, we sought to determine the impact of VEGFR2-positive
GrCD11b population on tumor growth and tumor angiogen-
esis. Because the percentage of VEGFR2-positive GrCD11b
cells is very small, we therefore sorted GrCD11b/VEGFR2	
cells and coinjected them with MC26 cells into Balb/c mice.
We did not observe a statistically significant decrease in tumor
growth from coinjection with GrCD11b/VEGFR2	 cells
compared to coinjection with the whole GrCD11b popula-
tion, which includes VEGFR2 cells (Figure 7E). In addition,
we found a small number of vital dye-labeled GrCD11b/
VEGFR2	 cells also incorporated into the tumor endothelium
when coinjected with MC26 cells (data not shown). Collectively,
these data suggest that GrCD11bVEGFR2 cells likely give
rise to the cells incorporated into tumor endothelium; however,
VEGFR2	 cells also have the potential under tumor conditions.
Finally, we examined the expression of endothelium markers
on GrCD11b cells of tumor mice. We observed 4.39 
0.56%, 6.71 1.02%, and 4.02 0.66% of the cells expressing
VEGFR2, VE-Cadherin, and both markers, respectively, indicat-
ing that GrCD11b cells are closely related to ECs. In addition,
GrCD11b cells from tumor-bearing mice had a significantly
increased number of VEGFR2, VE-Cadherin, and VEGFR2/
VE-Cadherin GrCD11b cells, compared with non-tumor-
bearing mice (p  0.01) (Figure 7F).
The expression of endothelial markers is dramatically
increased in GrCD11b cells residing in tumor
tissues, and GrCD11b cells acquired EC properties
in proangiogenic culture conditions
In recent years, there has been an increased recognition of
strong adaptive responses of non-tumor cells in response to
environmental stimuli. We hypothesized that GrCD11b cells
might have a plasticity in the tumor microenvironment. To exam-
ine this, we compared the endothelial marker expression of
GrCD11b cells residing in tumor tissues with those fromFigure 5. GrCD11bcells produced MMP9 that contributed to tumor angi-
ogenesis spleens of tumor-bearing mice. Very interestingly, the percent-
age of GrCD11b cells expressing both VE-Cadherin andA: 5  105 3LL cells and 0.5  105 GrCD11b cells with MMP9 null back-
ground were injected s.c. into C57Bl/6 mice. 3LL cells alone and VEGFR2 was dramatically increased in cells from tumor tissues
GrCD11bcells from wt tumor-bearing mice were used as controls. Results when compared to those from spleens (p  0.01) (Figure 8A),
were presented as the mean  SEM (8–12 mice per group). ‡, p  0.001,
suggesting that the tumor microenvironment may induce differ-§, p  0.05, compared to 3LL plus wt GrCD11b cells. *, p  0.05, com-
entiation of GrCD11b cells toward ECs. Growth factors in-pared to the 3LL cells alone.
B: CD31-positive blood vessels were counted in ten randomly selected fields fluence cell differentiation, and VEGF, bFGF, and IGF are impor-
from 4 independent 3LL tumors 14 days after the tumor inoculation. Results tant angiogenic factors. We therefore cultured GrCD11b
were presented as the mean  SEM. * and **, p  0.05; §, p  0.05.
cells on fibronectin-coated plates in the presence of VEGF,C: Gelatin zymography of sorted GrCD11b cells from the spleens of
bFGF, and IGF for a week in attempt to mimic the tumor microen-normal mice (lane 1) and tumor-bearing mice (lane 2) was shown.
D–E: MMP9 in situ hybridization showed more MMP9-positive cells in 14-day vironment. Under this condition, GrCD11b cells take up low-
tumor tissues derived from 3LL coinjected with tumor derived GrCD11b density lipoprotein (Dil-LDL) within a few hours of incubation,
cells (E) than 3LL alone (D). MMP9-positive cells were seen lining in the tumor
a property of ECs (Figure 8B). GrCD11b cells attached toendothelium as indicated by arrows (inset in E).
the dishes and displayed a cobblestone-like morphology (Figure
8C). The cultured GrCD11b cells express VEGFR2 and VE-
Cadherin cell surface markers (Figure 8C). Very interestingly,
sorted VEGFR2-negative GrCD11b cells express VEGFR2served “blue” (-gal-positive) tumor endothelium of large (Figure
and VE-Cadherin after one week in culture (Figure 8C). Further7C) and small vessels (Figure 7D) derived from coinjection of
analysis by flow cytometry confirmed that sorted VEGFR2-nega-tumor cells with GrCD11b of Rosa-26 mice. A costaining
tive GrCD11 cells express VEGFR2, VE-Cadherin, and bothwith a VE-Cadherin antibody confirmed that the -gal-positive
markers after one week in culture, with no statistical differencecells were indeed endothelium (Figure 7C). These data demon-
found when compared with sorted total GrCD11bpopulationstrate that GrCD11b cells have the potential to differentiate
under the same conditions (Figure 8D). These results are inand incorporate into tumor endothelium.
agreement with our early observation that GrCD11b/EPCs have been identified as VEGFR2-positive, and 4.39 
0.56% of GrCD11b cells also express VEGFR2; there- VEGFR2	 cells also gave rise to tumor endothelium and pro-
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Figure 6. MMP9 produced in tumor-derived
GrCD11b cells released VEGF in tumors pro-
moting angiogenesis; in BM, it released sKitL con-
tributing to GrCD11b cell production
A and B: Immunohistochemistry of VEGF/VEGFR2
complex as indicated by arrows in tumor sections
of MC26 coinjected with GrCD11b cells from
normal mice (A) and tumor-bearing mice (B).
C: VEGF release in culture media measured by
ELISA. MC26 tumor tissues were harvested 2
weeks after inoculation, cut into small pieces (0.5
mm size), and cultured in serum-free conditions
in a 24-well plate for 24 hr, with each well con-
taining 15 pieces of small tumor tissues. The results
were presented as the mean  SEM of 3 inde-
pendent experiments. * and **, p  0.01.
D: Transwell filters with HUVECs were placed into
a 24-well plate, which contains 15 pieces of tu-
mors in each well. A VEGF inhibitor (ExFlk at 1 
g/
ml) and an MMP inhibitor (GM6001 at 20 
M)
were included. Recombinant VEGF at 20 ng/ml
was used as a control. Migrated HUVECs were
counted 5 hr after incubation. *, p  0.05; **p, 
0.01.
E–G: Flow cytometry analysis of GrCD11b
cells in spleens (E), BM (F), and tumor tissues (G)
of C57BL/6 and MMP9 null mice with or without
3LL tumors 28 days after tumor implantation. n 
5 mice per group. *, p  0.01; **, p  0.05.
H: Confluent BM stromal cells were incubated
with GrCD11b cells. GM6001 at 20 
M was
included in the coculture with tumor-derived
GrCD11b cells. sKitL was measured in the cul-
ture media 24 hr after incubation by ELISA. * and
**, p  0.01.
moted tumor growth as total GrCD11b cells did (Figure 7E). Discussion
Together, our data demonstrate that GrCD11b cells have a
BM-derived cells play important roles in tumor vascular develop-certain plasticity and acquire EC properties in the tumor micro-
ment (De Palma et al., 2003; Luttun et al., 2002; Lyden et al.,environment in vivo and angiogenic conditions in vitro in a dy-
2001; Reyes et al., 2002). There are two major themes of re-namic manner.
search in this area. First, tumor vascular formation involvesTo assess the possible role of MMP9 in GrCD11b differ-
endothelial progenitors through vasculogenesis (Asahara et al.,entiation into ECs, we sorted those cells from MMP9 null and
1997; Carmeliet et al., 2001; Luttun et al., 2002; Lyden et al.,wt mice bearing 3LL tumors and cultured them under the same
2001; Reyes et al., 2002). Second, host inflammatory cells, in-proangiogenic conditions. MMP9 null GrCD11b cells dis-
played endothelial cell morphology and expressed both cluding mast cell and macrophages, infiltrate tumor tissues,
alter the microenvironment, and promote tumor angiogene-VEGFR2 and VE-Cadherin after one week in culture, with no
difference found when compared to wt GrCD11b cells (Fig- sis (Coussens et al., 2000; Kamate et al., 2002). Our data demon-
strate that myeloid immune suppressor GrCD11b cellsure 8C). This result suggests that MMP9 function does not affect
GrCD11b cell differentiation to ECs. directly contribute to tumor vascular development through
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Figure 7. GrCD11bcells directly incorporated
into tumor endothelium
A: 0.5  105 5-CFDA-labeled GrCD11b cells
and 5  105 MC26 cells were coinjected s.c. in
Balb/c mice. Tumors were harvested 21 days
after implantation and frozen sections were ex-
amined under fluorescence microscopy. CFDA-
labeled GrCD11b cells were observed to line
the tumor endothelium (arrow). DAPI staining for
nuclei.
B: Colocalization of GrCD11b cells with tumor
endothelium. Tumor sections were stained with
a CD31 antibody: CD31-positive endothelial cells
(upper panel) and CFDA-labeled GrCD11b
cells (arrow, middle panel) were colocalized in
tumor endothelium (lower panel).
C: -gal staining of 3LL tumor tissues derived from
coinjection of tumor cells with GrCD11b cells
of tumor-bearing Rosa-26 mice. The section was
costained with an anti-VE-Cadherin antibody
(red). -gal-positive cells were colocalized with
VE-Cadherin-positive tumor endothelium (solid
arrow). Open arrow indicates a surrounding host
derived vessel.
D: A small -gal-positive vessel is shown.
E: 5 105 MC26 cells plus 0.5  105 GrCD11b/
VEGFR2	 cells was injected s.c. in Balb/c mice.
MC26 cells plus whole GrCD11b cells were
used as controls. Tumor volume was measured.
Results are presented as the mean  SEM (3–4
mice per group) (p  0.02).
F: Quantification of GrCD11b cells expressing
VEGFR2, VE-Cadherin, and both markers in the
spleens of MC26 tumor-bearing mice and nor-
mal mice by flow cytometry (n  4 pairs). **, p 
0.01, *, p  0.05.
two major mechanisms: producing MMP9 and differentiating tumor development (Coussens et al., 2000; Huang et al., 2002).
We observed that MMP9, but not MMP2, is overproduced ininto ECs.
The importance of GrCD11b cells in tumor growth is not GrCD11b cells by zymography, and this production was
essential for their ability to promote tumor angiogenesis. Theseonly that they are significantly increased in tumor-bearing hosts,
but also that these cells constitute about 5% of the total cells data were confirmed by microarray analysis with the Affymetrix
U74AV2 array, which revealed a 5.4-fold increase in MMP9in tumor tissues. We hypothesize that GrCD11b cells may
not only be immune-suppressive but may also contribute to mRNA but no difference in 21 other MMPs (data not shown).
We found that MMP9 from GrCD11b cells of tumor-bearingtumor growth directly. We found that there are two mechanisms
by which GrCD11b cells promote tumor growth and enhance hosts regulates bioavailability of VEGF in tumors and promotes
tumor angiogenesis and vascular stability, as well as release oftumor angiogenesis. First, GrCD11b cells produce high lev-
els of MMP9, an important mediator in angiogenesis (Bergers sKitL in BM, potentially regulating the production and mobiliza-
tion of GrCD11b cells. Selective deletion of MMP9 inet al., 2000; Coussens et al., 2000; Heissig et al., 2002). Stromal
MMP9 was shown to regulate vascular stability by recruiting GrCD11b cells eliminated their ability to promote tumor
growth, and, in fact, led to inhibition of tumor formation. Thispericytes (Chantrain et al., 2004). Host contribution of MMP9
from tumor-infiltrating cells was shown to play a critical role in implies and is in agreement with the proposal that tumor angio-
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Figure 8. Tumor microenvironment and angio-
genic factors induced GrCD11b cell differen-
tiation toward ECs
A: The expression of VEGFR2 and VE-Cadherin in
GrCD11b cells from MC26 tumor tissues and
spleens of tumor-bearing mice was analyzed by
flow cytometry. Results are presented as the
mean  SEM from three experiments. * p  0.01.
B: GrCD11b cells took up LDL. Cultured
GrCD11b cells were incubated with fluores-
cent dye-labeled LDL for 2 hr. The micro images
were taken under a microscope.
C: GrCD11b cells differentiated into ECs
in vitro. Total GrCD11b cells (a and b),
GrCD11b/VEGFR2 cells (c and d) and
GrCD11b/VEGFR2	 (e and f) were sorted
from the spleens of MC26 tumor-bearing mice,
and MMP9 null GrCD11b cells (g and h) were
from the spleens of 3LL tumor-bearing MMP9 null
mice. The cells were cultured in the presence
of bFGF, VEGF, and IGF for a week. Cells were
stained with antibodies against VE-Cadherin (a,
c, e, and g), VEGFR2 (b, d, f, and h), and isotype
controls (i and j). The slides were costained with
DAPI, and analyzed by an Olympus fluorescence
microscope.
D: Sorted total GrCD11b cells and
GrCD11b/VEGFR2	 cells were cultured for a
week. The expression of VEGFR2 and VE-Cad-
herin on these cells was analyzed by flow cy-
tometry.
genesis can be targeted by transplantation of genetically modi- these cells develop into endothelial-like cells. They have in-
creased expression of ECs markers (Fernandez Pujol et al.,fied hematopoietic cells (De Palma et al., 2003).
The second mechanism is our finding that GrCD11b cells 2001). Although there are contradicting reports regarding devel-
opmental plasticity of adult progenitor cells (Joshi and Enver,directly incorporate into tumor endothelium in vivo. VEGFR2
GrCD11b cells are likely giving rise to tumor endothelium. 2002; Wagers et al., 2002), our results support that certain levels
of plasticity exist in the tumor microenvironment. Tumors thusHowever, cultured VEGFR2	 GrCD11b cells acquire the
expression of EC markers in the proangiogenic conditions can affect the differentiation of GrCD11b cells not only sys-
temically, but also locally.in vitro and incorporate into tumor endothelium in vivo, which
suggests that the participation of these cells in tumor progres- Studies from cancer patients showed GrCD11b cells
were composed of immature macrophages, immature DC, andsion is not static but rather dynamic. In agreement with this
observation, GrCD11b cells exhibited significantly increased immature myeloid cells at early stages of differentiation as well
as a small percentage (2%) of hematopoietic progenitor cellsexpression of several EC markers in the tumor microenviron-
ment in vivo and proangiogenic conditions in vitro, indicating (Almand et al., 2001). In characterizing GrCD11b cells, we
found that they contain cell subsets expressing c-kit (4.82 that these cells have significant plasticity. Our observation is
supported by several previous reports: immature DCs, in a tran- 0.51%), CD34 (7.1  0.95%), and Sca-1 (18  3.3%), markers
often found in progenitor cells. But GrCD11b cells expresssient stage of differentiation in the myeloid lineage, can form
cord-like structures in matrigel (Schmeisser et al., 2001). When both Gr and CD11b, unlike conventional myeloid progenitor
cells, and are therefore much more differentiated than classicalcultured in the presence of angiogenic factors, including VEGF,
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lations were collected for tumor growth, MMP9 zymography, cytospin, andprogenitors. The fact that these cells express markers for pro-
in vitro differentiation experiments.genitor cells indicates that they are likely immature myeloid cells
in an intermediate stage of differentiation. In addition, these
Cytospin and HE stainingcells express ECs markers, indicating their close relationship
Sorted Gr/CD11b cells were spun onto glycine-coated slides (Cytospin
with ECs. The GrCD11b cells are different from BM-derived 3, Shandon, PA). The cells were fixed in 4% paraformaldehyde and stained
EPCs that are described as CD11b-negative (Hattori et al., with HE.
2001). Therefore, GrCD11b cells may represent a new popu-
Isograft models of tumor biologylation of cells that have the potential to differentiate into ECs
MC26 or 3LL cells (5  105 cells), combined with GrCD11b cells (0.5 with particular relevance to tumor angiogenesis.
105), were injected subcutaneously (s.c.) into the right flank of Balb/c miceThe GrCD11b cells, as immature myeloid cells, have the
or C57Bl/6 mice, respectively. The size of tumors was determined by directability to migrate through tumor hosts, as do other immune
measurement of tumor dimensions at 2–3 day intervals using calipers. The
cells. It may be that tumors take advantage of this property of equation volume  length  (width)2  0.5 was used to calculate tumor
immune cells and recruit them to the tumor site. These immune volume.
cells produce high levels of MMP9, and also directly differentiate
and incorporate into the vascular endothelium, promoting tumor Magnetic resonance imaging
Anesthetized tumor-bearing mice were examined with a 3.0 Tesla MR scan-vascularization and tumor progression. The fact that these cells
ner (GE Medical Systems). Imaging included coronal 1 mm slice thicknessare overproduced, exist as immature myeloid cells in the tumor-
with 0.1 mm gap conventional gradient echo T1-weighted images beforebearing hosts, and can be reprogrammed is very important in
and after injection of 0.05 ml of GdDTPA (Magnevist). The total tumor volume
understanding tumor-host interactions.
was assessed in each MR examination by ROI-based volumetry. The tumor
We have shown that VEGF, a potent angiogenic factor abun- area was traced on the coronal T1-weighted image. To determine areas of
dantly expressed in tumors, regulates the production and im- little or no contrast enhancement (i.e., necrotic areas), coregistered precon-
mune suppression of GrCD11b cells in vivo. In this report, trast images were subtracted from postcontrast images; the pixels of the
generated difference image were counted to determine the area within thewe identify a novel function of these cells in promoting tumor
tumor that did not enhance with contrast.angiogenesis. It is conceivable that the tumor microenvironment
and VEGF modulate the production and differentiation of
ImmunohistochemistryGrCD11b cells, which then exhibit different functions, in-
Tumor sections were incubated with an anti-CD31 antibody (Pharmingen)
cluding host immune suppression and promotion of tumor angi- or anti-VEGF/VEGFR2 complex antibody (Brekken et al., 2000), respectively.
ogenesis. There are preclinical and clinical trials using anti-VEGF A biotinylated 2nd antibody was applied, followed by incubation with strepta-
antibody and all-trans-retinoic acid to induce the differentiation vidin-conjugated HRP. Peroxidase activity was localized with diaminobenzi-
dine (Vector Laboratories).of these cells in an attempt to improve host antitumor response
For CD31 and SMC double staining, frozen sections were blocked(Gabrilovich et al., 1999; Kusmartsev et al., 2003) (D. Gabrilo-
with M.O.M. solution (Vector Lab), incubated with antibodies to CD31 andvich, personal communication). Based on our findings, we sug-
to SMA (DAKO) overnight (4C), and visualized by using Texas Red-conju-
gest that cancer vaccine strategies directed toward enhancing gated goat anti-rat and Cy2-conjugated goat anti-mouse 2nd antibodies
the antitumor immune response should take these cells into (Jackson Immuno Research Laboratories).
account together with their proangiogenic properties of MMP9 For -galactocidase staining, tumor tissues from Rosa-26 mice were
stained with a X-gal solution, followed by costaining with an anti-VE-Cadherinproduction and plasticity. Therapeutic approaches directed at
antibody and an AP-conjugated 2nd antibody (Vector Lab).this aspect of the host-tumor interface may have synergistic
For apoptosis, frozen tumor sections were stained with ApopTag Plusimmune and antiangiogenic effectiveness.
Peroxidase in situ Apoptosis Detection Kit (Intergen). For hypoxia, one hour
before sacrifice, mice were i.p. injected with Hypoxyprobe-1 at 60 mg/kgExperimental procedures
(Chemicon International, Inc). Tumor tissues were processed and frozen
sections were incubated with Hypoxyprobe-1-MAb1 according to the manu-Cell lines and mice
facturer’s recommendation.MC26 colorectal cancer cell line, and Lewis lung carcinoma cell line (3LL),
were maintained per standard cell culture techniques.
Immunoassay for cytokines and chemokinesEight- to ten-week-old female Balb/c or C57Bl/6 mice and Rosa-26
Conditioned media and tissue lysates were analyzed for VEGF, TNF, andmice were purchased from Harlan Inc. (Indianapolis, IN) and Jackson Labora-
sKitL expression by ELISA using commercial kits (R&D Systems).tory (Bar Harbor, ME). MMP9 knockout mice (Vu et al., 1998) were back-
crossed into a C57Bl/6 background to n  10. The animals were housed in
In vitro cell migration assaypathogen-free units at Vanderbilt University Medical Center, in compliance
Human umbilical vein ECs (HUVECs) were seeded into the top chamber ofwith IACUC regulations.
Transwell filters (VWR Scientific) coated with fibronectin. The filters were
placed in a 24-well plate that contains 15 small pieces of tumor tissuesFlow cytometry analysis
(0.5 mm size) per well in serum-free media. Recombinant soluble VEGFR2Single cell suspensions were made from spleens and BM of normal and
(ExFlk) (Lin et al., 1998) at 1 
g/ml or MMP inhibitor GM6001 at 20 
M wastumor-bearing mice. For tumor tissues, we followed a published protocol
added into the bottom chamber. Migrated ECs were counted (8 fields/filter)(Ljung et al., 1989). These cells were labeled with fluorescence-conjugated
5 hr after incubation.antibodies (BD Pharmingen) and isotype-matched IgG controls. The cells
were analyzed on a FACScan flow cytometer (Becton Dickinson, Mountain
BM stromal cell cultureView, CA).
BM cells from Balb/c mice were seeded onto fibronectin coated 24-well
plates for 48 hr, and floating cells were removed by washing with PBS.Single-cell sorting
GrCD11b cells were seeded into either fresh wells or on top of theSplenocytes from normal or tumor-bearing mice were stained with fluores-
stromal cells in serum-free media. GM6001 at 20 
M was used. Conditionedcence-labeled antibodies and sorted with a FACStarPlus flow cytometer
(Becton Dickinson, Franklin Lakes, NJ). GrCD11b cells and the subpopu- media was collected 24 hr after the coculture for analysis of sKitL levels.
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immature myeloid cells in cancer patients: A mechanism of immunosuppres-In situ hybridization of MMP9
sion in cancer. J. Immunol. 166, 678–689.An 835 bp fragment of the 3UTR (Witty et al., 1995) was labeled with
digoxigenin according to manufacturer’s instructions (Roche). Tumor sec- Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T.,
tions were microwaved in 10 mM citrate (pH 6.0), treated with 5 
g/ml Witzenbichler, B., Schatteman, G., and Isner, J.M. (1997). Isolation of putative
proteinase K, and incubated with the labeled probe for 16 hr at 50C, followed progenitor endothelial cells for angiogenesis. Science 275, 964–967.
by incubation with an AP-labeled anti-DIG antibody and incubation with the
Bergers, G., Brekken, R., McMahon, G., Vu, T.H., Itoh, T., Tamaki, K., Tan-BCIP/NBT. The slides were counterstained with Contrast Green (Kirkegaard
zawa, K., Thorpe, P., Itohara, S., Werb, Z., and Hanahan, D. (2000). Matrixand Perry).
metalloproteinase-9 triggers the angiogenic switch during carcinogenesis.
Nat. Cell Biol. 2, 737–744.Zymography of MMP9
Cells were lysed in buffer containing 500 mM Tris-HCl (pH 7.4), 200 mM Brekken, R.A., Overholser, J.P., Stastny, V.A., Waltenberger, J., Minna, J.D.,
NaCl, 10 mM CaCl2, and 1% Triton X-100. Aliquots of 20 
g proteins were and Thorpe, P.E. (2000). Selective inhibition of vascular endothelial growth
analyzed by gelatin zymography on SDS-PAGE with substrate (1 mg/ml of factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF
gelatin). After electrophoresis, gels were washed in buffer (50 mM Tris-HCl antibody blocks tumor growth in mice. Cancer Res. 60, 5117–5124.
[pH 7.5] with 100 mM NaCl and 2.5% Triton X-100) followed by incubation
Bronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P.,with 50 mM Tris-HCL (pH 7.5) and 10 mM CaCl2 for 20 hr at 37C, and then Restifo, N.P., and Zanovello, P. (2000). Identification of a CD11b()/Gr-1()/stained with 0.25% Coomassie Brilliant Blue R-250.
CD31() myeloid progenitor capable of activating or suppressing CD8()
T cells. Blood 96, 3838–3846.
In vitro differentiation of GrCD11b cells
Bright GrCD11b cells and a subpopulation of cells were sorted from Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol,
M., Wu, Y., Bono, F., Devy, L., Beck, H., et al. (2001). Synergism betweenspleens of tumor-bearing mice by FACS, seeded on fibronectin-coated tis-
vascular endothelial growth factor and placental growth factor contributessue culture slides (Nalgene, Rochester, NY), and cultured at 37C. The media
to angiogenesis and plasma extravasation in pathological conditions. Nat.consists of 70% endothelial growth media (Clonetics Inc, Walkersville, MD)
Med. 7, 575–583.and 30% NIH3T3 culture media plus 20 ng/ml VEGF (NCI), 2.5 ng/ml IGF
(R&D Systems Inc, Minneapolis, MN), and 2 ng/ml bFGF (NCI). The cells Chantrain, C.F., Shimada, H., Jodele, S., Groshen, S., Ye, W., Shalinsky,
were processed for immunofluorescent staining with anti-VEGFR2, anti-VE- D.R., Werb, Z., Coussens, L.M., and DeClerck, Y.A. (2004). Stromal matrix
Cadherin antibodies (Santa Cruz), and appropriate Alexis-488 conjugated metalloproteinase-9 regulates the vascular architecture in neuroblastoma by
secondary antibodies (Molecular Probes, Eugene, OR), with nuclei stained promoting pericyte recruitment. Cancer Res. 64, 1675–1686.
with DAPI. The cells were examined under an Olympus IX70 microscope.
Coussens, L.M., and Werb, Z. (2002). Inflammation and cancer. Nature 420,For LDL uptake assay, GrCD11b cells were cultured on fibronectin-
860–867.coated wells for a week. The assay was carried out in the serum-free EBM
medium (Clonetics) in the presence of Dil-acLDL (Molecular Probes) at 10 Coussens, L.M., Tinkle, C.L., Hanahan, D., and Werb, Z. (2000). MMP-9

g/ml for 2–3 hr, then washed and examined. supplied by bone marrow-derived cells contributes to skin carcinogenesis.
Cell 103, 481–490.
GrCD11b cell labeling
De Palma, M., Venneri, M.A., Roca, C., and Naldini, L. (2003). TargetingGrCD11b cells were labeled with 5-CFDA SE (Molecular Probes) for
exogenous genes to tumor angiogenesis by transplantation of geneticallylong-term tracking of cells in vivo. A cell suspension containing labeled 0.5
modified hematopoietic stem cells. Nat. Med. 9, 789–795.105 GrCD11b cells, and 5  105 MC26 cells were coinjected s.c. into
the right flank of Balb/c mice. Tumors were removed 21 days after the Fernandez Pujol, B., Lucibello, F.C., Zuzarte, M., Lutjens, P., Muller, R., and
inoculation and cryopreserved in OCT (Sakura Finetek Inc.). Frozen sections Havemann, K. (2001). Dendritic cells derived from peripheral monocytes
were mounted on glass slides and stained with DAPI and CD31 antibody, express endothelial markers and in the presence of angiogenic growth fac-
and examined. tors differentiate into endothelial-like cells. Eur. J. Cell Biol. 80, 99–110.
Fridman, R., Toth, M., Chvyrkova, I., Meroueh, S.O., and Mobashery, S.Statistical analysis
(2003). Cell surface association of matrix metalloproteinase-9 (gelatinase B).The REML-based mixed effect model and ANOVA were used to analyze the
Cancer Metastasis Rev. 22, 153–166.differences of tumor growth. The rest data were analyzed by the Student’s
t test. All data were expressed as means  SEM, and differences were Gabrilovich, D.I., Nadaf, S., Corak, J., Berzofsky, J.A., and Carbone, D.P.
considered statistically significant when the p value  0.05. (1996). Dendritic cells in antitumor immune responses. II. Dendritic cells
grown from bone marrow precursors, but not mature DC from tumor-bearing
Acknowledgments mice, are effective antigen carriers in the therapy of established tumors.
Cell. Immunol. 170, 111–119.
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